PA5-56603

antibody from Invitrogen Antibodies

Targeting: FNDC1 bA243O10.1, dJ322A24.1, FNDC2, KIAA1866

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-56603

Provider

Invitrogen Antibodies

Product name

FNDC1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: ECYAEEDEFS GLETDTAVPT EEAYVIYDED YEFETSRPPT TTEPSTTATT PRVIPEEGAI SSFPEEEFDL AGRKRFVAPY VTYLNKDPSA PCSLTDALD Highest antigen sequence identity to the following orthologs: Mouse - 81%, Rat - 78%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.2 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway.

Yunwen C, Shanshan G, Zhifei B, Saijun C, Hua Y
Molecular medicine reports 2021 Jun;23(6)

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of FNDC1 in human cell line A-431 shows positivity in nucleus but excluded from the nucleoli. Samples were probed using a FNDC1 Polyclonal Antibody (Product # PA5-56603).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2. The silencing of FNDC1 inhibits the tumorigenesis of BC. (A) Expression of FNDC1 in normal breast cell and BC cells were assayed by western blotting. (B) BC cells were transfected as indicated for 24 h, after which the protein levels of FNDC1 were measured by western blotting. (C) BC cells were transfected as indicated, after which the cell viability was measured by a Cell Counting kit-8 assay at different time points. (D) BC cells were transfected as indicated, after which a colony formation assay was performed. (E) BC cells were transfected as indicated, after which a wound healing assay was conducted to measure the migration ability. (F) BC cells were transfected as indicated, after which a Transwell assay was performed to measure the invasive ability. (G) BC cells were transfected as indicated for 24 h, after which the expression levels of the indicated proteins were measured by western blotting. The data are presented as the mean +- standard deviation. The experiments were performed at least three times. *P

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 3. The silencing of FNDC1 leads to inhibition of the PI3K/Akt signaling pathway. (A and B) BC cells were transfected as indicated for 24 h, after which the expression levels of the indicated proteins were measured by western blotting. The data are presented as the mean +- standard deviation. The experiments were performed at least three times. **P